Pharmacodynamic profiles of ketamine (R)-and (S)-with 5-day inpatient infusion for the treatment of complex regional pain syndrome

Pain Physician

Volumn 13, Issue 4, 2010, Pages 379-387

  Goldberg, Michael E ^a   Torjman, Marc C ^a   Schwartzman, Robert J ^b   Mager, Donald E ^c   Wainer, Irving W ^d  

^a Department of Anesthesiology   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Chronic pain; CRPS; Enantiomers; Ketamine; Norketamine; Pharmacodynamics

Indexed keywords

KETAMINE; MIDAZOLAM;

ADULT; ANALGESIA; ARTICLE; CLINICAL ARTICLE; COMPLEX REGIONAL PAIN SYNDROME; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHORIA; ENANTIOMER; FEMALE; HALLUCINATION; HOSPITAL PATIENT; HUMAN; HYPOXIA; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; OBSERVATIONAL STUDY; PAIN ASSESSMENT; RACEMIZATION; RESTLESSNESS; TACHYCARDIA; TREATMENT DURATION;

ADOLESCENT; ADULT; ANALGESICS; COMPLEX REGIONAL PAIN SYNDROMES; DRUG ADMINISTRATION SCHEDULE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STEREOISOMERISM; YOUNG ADULT;

EID: 77954986108     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Schwartzman RJ, Alexander GM, Gro-thusen J. Pathophysiology of complex regional pain syndrome. Expert Rev Neurother 2006; 6:669-681.
2. Schwartzman RJ, McLellan TL. Reflex sympathetic dystrophy. A review. Archives of Neurology 1987; 44:555-561.
3. Schwartzman RJ, Popescu A. Reflex sympathetic dystrophy. Curr Rheumatol Rep 2002; 4:165-169.
4. Bruehl S, Harden RN, Galer BS, Saltz S, Bertram M, Backonja M, Gayles R, Ru-din N, Bhugra MK, Stanton-Hicks M. External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria. International Association for the Study of Pain. Pain 1999; 81:147-154.
5. Burton AW, Bruehl S, Harden RN. Current diagnosis and therapy of complex regional pain syndrome: refining diagnostic criteria and therapeutic options. Expert Review of Neurotherapeutics 2005; 5:643-651.
6. Bell RF. Low-dose subcutaneous ket-amine infusion and morphine tolerance. Pain 1999; 83:101-103.
7. Clark JL, Kalan GE. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tol-erant patient. J Pain Symptom Manage 1995; 10:310-314.
8. Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: A double-blind, cross-over comparison with morphine and placebo. Pain 1994; 58:347-354.
9. Harbut RE, Correll GE. Successful treatment of a nine-year case of complex regional pain syndrome type 1 (reflex sympathetic dystrophy) with intravenous ketamine-infusion therapy in a warfarin-anticoagulated adult female patient. Am Acad Pain Med 2002; 3:147-155.
10. Correll GE, Maleki J, Gracely EJ, Muir JJ, Harbut RE. Subanesthetic ketamine infusion therapy: A retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med 2004; 5:263-275.
11. Kvarnstrom A, Karlsten R, Quiding H, Emanuelsson BM, Gordh T. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. Acta Anaesthesiol Scand 2003; 47:868-877.
12. Veldman PH, Goris RJ. Multiple reflex sympathetic dystrophy. Which patients are at risk for developing a recurrence of reflex sympathetic dystrophy in the same or another limb. Pain 1996; 64:463-466.
13. Maleki J, LeBel AA, Bennett GJ, Schwartz-man RJ. Patterns of spread in complex regional pain syndrome type I (reflex sympathetic dystrophy). Pain 2000; 88:259-266.
14. Øye I, Paulsen O, and Maurset A. Effects of ketamine on sensory perception: Evidence for a role of N-methyl-D-aspar-tate receptors. J Pharmacol Exp Ther 1992; 260: 1209-1213.
15. White PF, Schuettler J, Shafer A, Stanski DR, Horai Y, and Trevor AJ. Comparative pharmacology of the ketamine isomers. Br J Anaesthesia 1985; 57:197-203.
16. Ebert B, Mikkelsen S, Thorkildsen C, and Borgbjerg FM. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 1997; 333:99-104.
17. Øye I, Rabben T, Fagerlund TH. Analgesic effect of ketamine, an NMDA receptor antagonist, in a patient with neuropathic pain. J Norw Med Assoc 1996; 116:3130-3131.
18. Rabben T, Skjelbred P and Øye I. Prolonged analgesic effect of ketamine, an N-Methyl-D- Aspartate receptor inhibitor, in patients with chronic pain. Pharmacol Exp Ther 1999; 289:1060-1066.
19. Strigo IA., Duncan GH, Bushnell MC, Boivin M, Wainer I, Rodriguez Rosas ME, Persson J. The effects of racemic ketamine on painful stimulation of skin and viscera in human subjects. Pain 2005; 113:255-264.
20. Baron R, Fields HL, Janig W, Kitt C, Levine JL. National institute of health workshop: Reflex sympathetic dystrophy/complex regional pain syndromes: state of sciences. Anesth Analg 2002; 95:1812-1816.
21. Kiefer RT, Rohr P, Ploppa A, Dieterich HJ, Grothusen J, Koffler S, Altemey-er KH, Unertl K, Schwartzman RJ. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: An open-label phase II study. Pain Med 2008; 9:1173-1201.
22. Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY, Dah-an A. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009; 145:304-311.
23. Schwartzman RJ, Alexander GM, Gro-thusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study. Pain 2009; 147:107-115.
24. Koffler SP, Hampstead BM, Irani F, Tinker J, Kiefer RT, Rohr P, Schwartzman RJ. The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome. Arch Clin Neuropsychol 2007; 22:719-729.
25. Goldberg ME, Domsky R, Scaringe D, Hirsh R, Dotson J, Sharaf I, Torjman MC, Schwartzman RJ. Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome. Pain Physician 2005; 8:175-179.
26. Jevtovic-Todorovic V, Wozniak DF, Ben-shoff ND, Olney JW. A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide. Brain Research 2001; 895:264-267.
27. Rodriguez Rosas ME, Patel S, Wainer IW. Determination of the enantiomers of ketamine and norketamine in human plasma by enantioselective liquid chromatography-mass spectrometry. J Chromatog B 2003; 794:99-108.
28. Geisslinger G, Hering W, Thomann P, Knoll R, Kamp HD. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using stereoselective analytical method. Br J Anaesthesia 1993; 70:666-671.
29. Ihmsen H, Geisslinger G, Schuttler J. Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. Clin Pharmacol Ther 2001; 70:431-438.
30. Holtman JR, Crooks PA, Johnson-Hardy JK, Hojomat M, Kleven M, Wala EP. Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behavior 2008; 90: 676-685.
31. Yanagihara Y, Ohtani M, Kariya S, Uchi-no K, Hiraishi T, Ashizawa N, Aoyamo T, Yamamura Y, Yamada Y, Iga T. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Bopharmaceutics Drug Disp 2003; 24:37-43.